Icatibant, a New Bradykinin-Receptor Antagonist, in Hereditary Angioedema

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Search: onr:"swepub:oai:lup.lub.lu.se:c47411d8-02ff-4eb4-8169-1470cf8f6fa4" > Icatibant, a New Br...

1 of 1
Previous record
Next record
To hitlist

Details
MARC

Cicardi, M. (author)

Icatibant, a New Bradykinin-Receptor Antagonist, in Hereditary Angioedema

Article/chapterEnglish2010

Publisher, publication year, extent ...

2010

Numbers

LIBRIS-ID:oai:lup.lub.lu.se:c47411d8-02ff-4eb4-8169-1470cf8f6fa4
https://lup.lub.lu.se/record/1677818URI
https://doi.org/10.1056/NEJMoa0906393DOI

Supplementary language notes

Language:English
Summary in:English

Part of subdatabase

SwePubSwePub

Classification

Subject category:art swepub-publicationtype
Subject category:ref swepub-contenttype

Notes

BACKGROUND Hereditary angioedema is characterized by recurrent attacks of angioedema of the skin, larynx, and gastrointestinal tract. Bradykinin is the key mediator of symptoms. Icatibant is a selective bradykinin B2 receptor antagonist. METHODS In two double-blind, randomized, multicenter trials, we evaluated the effect of icatibant in patients with hereditary angioedema presenting with cutaneous or abdominal attacks. In the For Angioedema Subcutaneous Treatment (FAST) 1 trial, patients received either icatibant or placebo; in FAST-2, patients received either icatibant or oral tranexamic acid, at a dose of 3 g daily for 2 days. Icatibant was given once, subcutaneously, at a dose of 30 mg. The primary end point was the median time to clinically significant relief of symptoms. RESULTS A total of 56 and 74 patients underwent randomization in the FAST-1 and FAST-2 trials, respectively. The primary end point was reached in 2.5 hours with icatibant versus 4.6 hours with placebo in the FAST-1 trial (P=0.14) and in 2.0 hours with icatibant versus 12.0 hours with tranexamic acid in the FAST-2 trial (P<0.001). In the FAST-1 study, 3 recipients of icatibant and 13 recipients of placebo needed treatment with rescue medication. The median time to first improvement of symptoms, as assessed by patients and by investigators, was significantly shorter with icatibant in both trials. No icatibant-related serious adverse events were reported. CONCLUSIONS In patients with hereditary angioedema having acute attacks, we found a significant benefit of icatibant as compared with tranexamic acid in one trial and a nonsignificant benefit of icatibant as compared with placebo in the other trial with regard to the primary end point. The early use of rescue medication may have obscured the benefit of icatibant in the placebo trial. (Funded by Jerini; ClinicalTrials.gov numbers, NCT00097695 and NCT00500656.)

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

Banerji, A. (author)
Bracho, F. (author)
Malbran, A. (author)
Rosenkranz, B. (author)
Riedl, M. (author)
Bork, K. (author)
Lumry, W. (author)
Aberer, W. (author)
Bier, H. (author)
Bas, M. (author)
Greve, J. (author)
Hoffmann, T. K. (author)
Farkas, H. (author)
Reshef, A. (author)
Ritchie, B. (author)
Yang, W. (author)
Grabbe, J. (author)
Kivity, S. (author)
Kreuz, W. (author)
Levy, R. J. (author)
Luger, T. (author)
Obtulowicz, K. (author)
Schmid-Grendelmeier, P. (author)
Bull, C. (author)
Sitkauskiene, B. (author)
Smith, W. B. (author)
Toubi, E. (author)
Werner, SonjaLund University,Lunds universitet,Lungmedicin, allergologi och palliativ medicin,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Respiratory Medicine, Allergology, and Palliative Medicine,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine(Swepub:lu)lung-swe (author)
Anne, S. (author)
Bjorkander, J. (author)
Bouillet, L. (author)
Cillari, E. (author)
Hurewitz, D. (author)
Jacobson, K. W. (author)
Katelaris, C. H. (author)
Maurer, M. (author)
Merk, H. (author)
Bernstein, J. A. (author)
Feighery, C. (author)
Floccard, B. (author)
Gleich, G. (author)
Hebert, J. (author)
Kaatz, M. (author)
Keith, P. (author)
Kirkpatrick, C. H. (author)
Langton, D. (author)
Martin, L. (author)
Pichler, C. (author)
Resnick, D. (author)
Wombolt, D. (author)
Fernandez Romero, D. S. (author)
Zanichelli, A. (author)
Arcoleo, F. (author)
Knolle, J. (author)
Kravec, I. (author)
Dong, L. (author)
Zimmermann, J. (author)
Rosen, K. (author)
Fan, W. -T. (author)
Lungmedicin, allergologi och palliativ medicinSektion II (creator_code:org_t)

Related titles

In:New England Journal of Medicine363:6, s. 532-5410028-4793

Internet link

Find in a library

New England Journal of Medicine (Search for host publication in LIBRIS)

To the university's database

1 of 1
Previous record
Next record
To hitlist

Find more in SwePub

By the author/editor: Cicardi, M.; Banerji, A.; Bracho, F.; Malbran, A.; Rosenkranz, B.; Riedl, M.; show more...; Bork, K.; Lumry, W.; Aberer, W.; Bier, H.; Bas, M.; Greve, J.; Hoffmann, T. K.; Farkas, H.; Reshef, A.; Ritchie, B.; Yang, W.; Grabbe, J.; Kivity, S.; Kreuz, W.; Levy, R. J.; Luger, T.; Obtulowicz, K.; Schmid-Grendelme ...; Bull, C.; Sitkauskiene, B.; Smith, W. B.; Toubi, E.; Werner, Sonja; Anne, S.; Bjorkander, J.; Bouillet, L.; Cillari, E.; Hurewitz, D.; Jacobson, K. W.; Katelaris, C. H.; Maurer, M.; Merk, H.; Bernstein, J. A.; Feighery, C.; Floccard, B.; Gleich, G.; Hebert, J.; Kaatz, M.; Keith, P.; Kirkpatrick, C. ...; Langton, D.; Martin, L.; Pichler, C.; Resnick, D.; Wombolt, D.; Fernandez Romero ...; Zanichelli, A.; Arcoleo, F.; Knolle, J.; Kravec, I.; Dong, L.; Zimmermann, J.; Rosen, K.; Fan, W. -T.; show less...

About the subject

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Clinical Medicin ...; and Respiratory Medi ...

Articles in the publication: New England Jour ...

By the university: Lund University

Search outside SwePub

Extend your search to:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se